Research and Markets (http://www.researchandmarkets.com/research/hzz8lv/oropharyngeal) has announced the addition of the "Oropharyngeal Cancer - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Oropharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Oropharyngeal Cancer Overview
  3. Therapeutics Development
  4. Pipeline Products for Oropharyngeal Cancer - Overview
  5. Pipeline Products for Oropharyngeal Cancer - Comparative Analysis
  6. Oropharyngeal Cancer - Therapeutics under Development by Companies
  7. Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes
  8. Oropharyngeal Cancer - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Oropharyngeal Cancer - Products under Development by Companies
  13. Oropharyngeal Cancer - Products under Investigation by Universities/Institutes
  14. Oropharyngeal Cancer - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Genticel S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • PNP Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • VLPbio

For more information visit http://www.researchandmarkets.com/research/hzz8lv/oropharyngeal